In diabetic IRI model, Dapagliflozin can effectively improve FAO dysfunction and inhibit abnormal glycolysis by activating SIRT3/PGC-1α signaling pathway, thus providing renal protection (Li H. et al., 2024). Here, SIRT3 is linked to diabetes mellitus.